Nasdaq
$19.15▼ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $853.4MShares out 44.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
30- 10.16After-hours26.10.17 05:104Ownership#●●●
Beta Bionics, Inc.
Mark Hopman, an officer of Beta Bionics, has executed a power of attorney granting Stephen Feider, Thomas Sohn, and Alison Kincade the authority to file SEC documents, including Forms 3, 4, 5, and Form 144. This action formalizes the legal process for the officer to comply with reporting requirements under Section 16 of the Securities Exchange Act.…more
$19.15-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Regular26.10.08 03:56SCHEDULE 13GOwnership
Beta Bionics, Inc.
T. Rowe Price Associates, Inc. has filed a Schedule 13G regarding its beneficial ownership in Beta Bionics, Inc. This filing serves to formally disclose the investment position held by the reporting entity.…more
$19.15-0.13%vs prev closeView filingShare - 10.5After-hours26.10.06 06:114Ownership
Beta Bionics, Inc.
Beta Bionics insider Mark Hopman filed a Form 4 on October 1, 2026, to report changes in his beneficial ownership of company securities. This filing serves as a standard disclosure regarding equity holdings by company management.…more
$19.15-0.13%vs prev closeView filingShare
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.22Pre-market26.09.22 20:30#●●●#●●●
Beta Bionics Partners with Senseonics for Diabetes Solution Integration…more
Beta Bionics has entered a partnership to integrate its automated insulin delivery systems with Senseonics' continuous glucose monitoring technology. The companies expect to launch the integrated solution in the fourth quarter of 2026 to expand device options for patients.…more
$19.15-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17After-hours26.09.18 05:05
●●●●●●●● ●●●●● ●●●●●●
Beta Bionics has closed a public offering of common stock, raising approximately $172.5 million in gross proceeds. The issuance of new shares will result in dilution for existing shareholders.…more
$19.15-0.13%vs prev close - 9.16Overnight26.09.16 16:56
●●●●●●●● ●●●●● ●●●●●●
Beta Bionics has priced a $150 million public offering consisting of common shares and pre-funded warrants. This capital raise may lead to shareholder dilution, which is typically viewed negatively by investors.…more
$19.15-0.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report